Dec 22, 2022 | Diane Hunter
I am a five-year multiple myeloma (MM) survivor, taking Revlimid and having quarterly Zometa infusions for bone strengthening. I have been thinking about having a conversation with my oncologist about is it necessary for me to continue my maintenance treatment. At the...
Dec 19, 2022 | Linda Huguelet
In some ways, a decade seems like a lifetime, but in other ways time flies by. 2013 was my first American Society of Hematology (ASH) Annual Meeting. That annual meeting, like the one this year, was held in New Orleans. The location may have been the same, but the...
Dec 16, 2022 | Sheri Baker
Three years ago, when I attended the American Society of Hematology (ASH) Annual Meeting, the darling of the dance was Darzalex® (daratumumab). They combined Darzalex® with everything and with great results. The past couple of years CAR-T therapy took over as the most...
Dec 11, 2022 | Jill Zitzewitz
The very first session I attended at this year’s American Society of Hematology (ASH) Annual Meeting was a Friday Satellite Symposium sponsored by Clinical Care Options and the International Myeloma Foundation. The symposium title, “A Conversation with the Myeloma...
